Share Email Print

Proceedings Paper

Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer
Author(s): Diana C. Hsiung Stripp M.D.; Rosemarie Mick; Timothy C. Zhu; Richard Whittington; Debbie Smith R.N.; Andreea Dimofte; Jarod C. Finlay; Jeremy Miles; Theresa M. Busch; Daniel Shin; Alex Kachur; Zelig A. Tochner M.D.; S. Bruce Malkowicz; Eli Glatstein M.D.; Stephen M. Hahn
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Therapeutic options for patients with locally recurrent prostate cancer after treatment with radiation therapy are limited. An ongoing Phase I trial of interstitial photodynamic therapy (PDT) with the photosensitizer motexafin lutetium (MLu) was initiated in year 2000 for men with locally recurrent prostate cancer. The primary objective of this trial is to determine the maximally tolerated dose of motexafin lutetium-mediated PDT. Twelve men with biopsy-proven recurrent prostate cancer and no evidence of distant metastatic disease have been enrolled. Pre-treatment evaluation included an MRI of the prostate, bone scan, laboratory studies, cystoscopy, and transrectal ultrasound. Treatment plans were generated based upon the ultrasound findings. PDT dose was escalated by increasing the motexafin lutetium dose, increasing the 732 nm light dose, and decreasing the drug-light interval. Motexafin lutetium doses ranged from 0.5 to 2 mg/kg administered IV 3, 6, or 24 hours prior to 732 nm light delivery. The light dose measured in real time with in situ spherical detectors was 25-100 J/cm2 for all patients. Light was delivered through optical fibers inserted through a transperineal brachytherapy template in the operating room and optical property measurements were made before and after light therapy. Prostate biopsies were obtained before and after light delivery for spectrofluorometric measurements of photosensitizer uptake. Twelve patients have completed protocol treatment on eight dose levels without dose-limiting toxicity. Grade I PDT-related genitourinary symptoms were observed. One patient had Grade II urinary urgency that was urinary catheter-related. No rectal or other GI PDT-related toxicities were observed. Measurements of motexafin lutetium in prostate tissue demonstrated the presence of photosensitizer at all dose levels. Conclusions: Motexafin lutetium-mediated PDT designed to treat comprehensively the entired prostate gland has been well-tolerated at the doses studied to date.

Paper Details

Date Published: 14 June 2004
PDF: 12 pages
Proc. SPIE 5315, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIII, (14 June 2004); doi: 10.1117/12.529181
Show Author Affiliations
Diana C. Hsiung Stripp M.D., Univ. of Pennsylvania (United States)
Rosemarie Mick, Univ. of Pennsylvania (United States)
Timothy C. Zhu, Univ. of Pennsylvania (United States)
Richard Whittington, Univ. of Pennsylvania (United States)
Debbie Smith R.N., Univ. of Pennsylvania (United States)
Andreea Dimofte, Univ. of Pennsylvania (United States)
Jarod C. Finlay, Univ. of Pennsylvania (United States)
Jeremy Miles, Univ. of Pennsylvania (United States)
Theresa M. Busch, Univ. of Pennsylvania (United States)
Daniel Shin, Univ. of Pennsylvania (United States)
Alex Kachur, Univ. of Pennsylvania (United States)
Zelig A. Tochner M.D., Univ. of Pennsylvania (United States)
S. Bruce Malkowicz, Univ. of Pennsylvania (United States)
Eli Glatstein M.D., Univ. of Pennsylvania (United States)
Stephen M. Hahn, Univ. of Pennsylvania (United States)

Published in SPIE Proceedings Vol. 5315:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIII
David Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top